Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.34 |
| ▸ | KMO | O15229 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 6/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 2/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.32 |
| ▸ | INSR | P06213 | 1/20 | 0.32 |
| ▸ | FBP1 | P09467 | 1/20 | 0.32 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.32 |
| ▸ | FLT4 | P35916 | 1/20 | 0.32 |
| ▸ | CLK1 | P49759 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6487453 | 0.82 | ALDH1A1 (0.34) | ALDH1A1MAPK1KMOAPPEGFR | |
| SCHEMBL4947246 | 0.79 | EGFR (0.47) | ALDH1A1DOT1LEGFRKDRDYRK1A | |
| SCHEMBL6479935 | 0.79 | ALDH1A1 (0.32) | ALDH1A1MAPK1EGFRERBB2 | |
| SCHEMBL14214685 | 0.72 | MAPK1 (0.55) | ALDH1A1MAPK1APPEGFRKDR | |
| SCHEMBL10639151 | 0.71 | ALDH1A1 (0.47) | ALDH1A1MAPK1KMOAPPTSHR | |
| SCHEMBL10151137 | 0.70 | KDR (0.49) | HDAC3HDAC1HDAC2HDAC6KDR | |
| SCHEMBL1042543 | 0.69 | ALDH1A1 (0.47) | ALDH1A1APPTSHR | |
| SCHEMBL27876061 | 0.69 | CSF1R (0.49) | EGFRKDRPDGFRBCSF1R | |
| SCHEMBL715925 | 0.67 | HSD17B10 (0.39) | ALDH1A1DYRK1ACLK1 | |
| SCHEMBL14107188 | 0.67 | ALDH1A1 (0.45) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1218360-B1 | TRIAZINE KINASE INHIBITORS | AMGEN INC (US) | 2008-05-28 | — | — | EP | disclosed |
| US-7074789-B2 | Kinase inhibitors | AMGEN INC. (US) | 2006-07-11 | — | — | US | disclosed |
| US-6881737-B2 | Substituted triazinyl acrylamide derivatives and methods of use | AMGEN INC. (US) | 2005-04-19 | — | — | US | disclosed |
| US-6864255-B2 | Substituted triazinyl amide derivatives and methods of use | AMGEN INC. (US) | 2005-03-08 | — | — | US | disclosed |
| US-20040116388-A1 | triazine compoound inhibitors of enzymes that catalyze phosphoryl transfer and/or that bind ATP/GTP nucleotides | AMGEN INC. | 2004-06-17 | — | — | US | disclosed |
| EP-1390354-A1 | TRIAZINYL ACRYLAMIDE DERIVATIVES AS KINASE INHIBITORS | Amgen Inc. (US) | 2004-02-25 | — | — | EP | disclosed |
| US-20030139416-A1 | Substituted triazinyl acrylamide derivatives and methods of use | AMGEN INC. | 2003-07-24 | — | — | US | disclosed |
| US-20030087908-A1 | Substituted triazinyl amide derivatives and methods of use | AMGEN INC. | 2003-05-08 | — | — | US | disclosed |
| WO-2002083653-A1 | TRIAZINYL ACRYLAMIDE DERIVATIVES AS KINASE INHIBITORS | AMGEN INC. (US) | 2002-10-24 | — | — | WO | disclosed |
| EP-1218360-A1 | TRIAZINE KINASE INHIBITORS | Amgen Inc., (US) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001025220-A1 | TRIAZINE KINASE INHIBITORS | AMGEN INC. (US) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139416-A1 | Substituted triazinyl acrylamide derivatives and methods of use | PKD1, PKD2, GLS | ALDH1A1 1130/4885HDAC3 584/4885HDAC1 2454/4885 |
| US-20030087908-A1 | Substituted triazinyl amide derivatives and methods of use | FLT4, FLT1, VEGFA | ALDH1A1 868/4885HDAC3 10/4885HDAC1 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.